DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody-Drug Conjugates for Acute Leukemia

This article belongs to the Special Issue Molecular Targets and Therapeutic Pathways in Cancer.

Bibliographic Details
Authors:	Pettenger Willey, Camryn M., Laszlo, George S., Gang, Margery, Cole, Frances M., Godwin, Colin D., Erraiss, Sarah, Chanana, Pritha, Kehret, Allie R., Li, Junyang, Barton, Jacob W., Yochim, Meghann M., Rodríguez-Arbolí, Eduardo, Walter, Roland B.
Format:	article
Status:	Published version
Publication Date:	2025
Country:	España
Institution:	Consejo Superior de Investigaciones Científicas (CSIC)
Repository:	DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:	oai:digital.csic.es:10261/420111
Online Access:	http://hdl.handle.net/10261/420111 https://api.elsevier.com/content/abstract/scopus_id/105027635802
Access Level:	Open access
Keyword:	CD22 CD33 CRISPR/Cas9 Acute leukemia Calicheamicin Drug screen Gemtuzumab ozogamicin Inotuzumab ozogamicin

Description
Summary:	This article belongs to the Special Issue Molecular Targets and Therapeutic Pathways in Cancer.